ReviewAnnals of translational medicine2017
The respiratory microbiome in idiopathic pulmonary fibrosis.
Review in Annals of translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 40 citations in OpenAlex.
- Single-cell RNA sequencing reveals aberrant airway epithelial-immune cell cross-talk in pulmonary fibrosis.ERJ open research · 2026Article
- Persistent microbial infections and idiopathic pulmonary fibrosis - an insight intoFrontiers in cellular and infection microbiology · 2024Review
- Lung-gut axis of microbiome alterations following co-exposure to ultrafine carbon black and ozone.Particle and fibre toxicology · 2023Article
- Article
- Sputum Microbiota in Coal Workers Diagnosed with Pneumoconiosis as Revealed by 16S rRNA Gene Sequencing.Life (Basel, Switzerland) · 2022Article
- The Role of Microbiome and Virome in Idiopathic Pulmonary Fibrosis.Biomedicines · 2021Review
- Changes in Neutrophil-Lymphocyte or Platelet-Lymphocyte Ratios and Their Associations with Clinical Outcomes in Idiopathic Pulmonary Fibrosis.Journal of clinical medicine · 2021Article
- The Respiratory Microbiome in Chronic Hypersensitivity Pneumonitis Is Distinct from That of Idiopathic Pulmonary Fibrosis.American journal of respiratory and critical care medicine · 2021Article
- Gut-Lung Axis in COVID-19.Interdisciplinary perspectives on infectious diseases · 2021Review
- Microbiome dysbiosis in lung cancer: from composition to therapy.NPJ precision oncology · 2020Review
- Dual and mutual interaction between microbiota and viral infections: a possible treat for COVID-19.Microbial cell factories · 2020Review
- Aesculetin Attenuates Alveolar Injury and Fibrosis Induced by Close Contact of Alveolar Epithelial Cells with Blood-Derived Macrophages via IL-8 Signaling.International journal of molecular sciences · 2020Article
- Assessment of the lung microbiota in dogs: influence of the type of breed, living conditions and canine idiopathic pulmonary fibrosis.BMC microbiology · 2020Article
- The influence of the microbiome on respiratory health.Nature immunology · 2019Review
- Pharmacotherapy and adjunctive treatment for idiopathic pulmonary fibrosis (IPF).Journal of thoracic disease · 2019Review
- The contribution of infection and the respiratory microbiome in acute exacerbations of idiopathic pulmonary fibrosis.European respiratory review : an official journal of the European Respiratory Society · 2019Review
- Dynamic Changes in the Microbiome and Mucosal Immune Microenvironment of the Lower Respiratory Tract by Influenza Virus Infection.Frontiers in microbiology · 2019Article
- Lung Diseases: Chronic Respiratory Infections.International journal of molecular sciences · 2018Article
- Fibrosis: Lessons from OMICS analyses of the human lung.Matrix biology : journal of the International Society for Matrix Biology · 2018Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease of unknown cause. Current evidence suggests that it arises in genetically susceptible individuals as a consequence of an aberrant wound-healing response following repetitive alveolar injury. Overt respiratory infection and immunosuppression carry a high mortality, while polymorphisms in genes related to epithelial integrity and host defence predispose to IPF. Recent advances in sequencing technologies have allowed the use of molecular microbial technologies to characterise the respiratory microbiota in patients with IPF. Studies have suggested that changes in the overall bacterial burden are related to disease progression and highlighted significant differences between the microbiota in IPF subjects and healthy controls. Indeed differences in the microbiota between IPF patients may differentiate those with stable compared to progressive disease. As our understanding of the IPF microbiome evolves, along with refinement and advances in sampling and sequencing methodologies we may be able to use microbial signatures as a biomarker to guide prognostication and even treatment stratification in this devastating disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.